Lantern Pharma Inc（LTRN）资讯与事件LTRNLantern Pharma Inc

Lantern Pharma Receives Approval for Phase 2 HARMONIC Trial in Taiwan

Lantern Pharma announced that it has received regulatory and IRB approvals in Taiwan to open the next stage of its Phase 2 HARMONIC trial of LP-300. The Taiwan Food and Drug Administration, TFDA, approved the amended protocol earlier in September, and the lead Taiwan site received local Institutional Review Board, IRB, approval on September 29, 2026. The lead site is now open to accrual and actively screening patients. The approval also allows additional Taiwan sites to proceed with their own IRB reviews. Lantern anticipates IRB approval in an additional two sites during Q4.

Lantern Pharma Issues 3,669,725 Shares at $1.09 Each

Lantern Pharma announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 3,669,725 shares of its common stock at a purchase price of $1.09 per share in a registered direct offering. In addition, in a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 shares of common stock. The warrants will have an exercise price of $1.09 per share, will be exercisable beginning on the effective date of, and subject to, approval by the company's stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants, and will expire five years following the Stockholder Approval. The closing of the offering is expected to occur on or about September 30, subject to the satisfaction of customary closing conditions. Rodman & Renshaw is acting as the exclusive placement agent for the offering.

Lantern Pharma Receives Patent Allowance for Blood Cancer Treatment

Lantern Pharma announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, titled "Method for Treating Blood Cancers," with claims directed to the use of the company's drug candidate LP-284 to treat patients with mantle cell lymphoma, double-hit lymphoma, and other blood cancers. The allowed claims cover methods of treating a subject diagnosed with blood cancer by administering an effective amount of LP-284, when the cancer is mantle cell lymphoma or double-hit lymphoma. Additional allowed claims cover the co-administration of LP-284 with a second anti-cancer agent selected from: DNA damaging agents, glucocorticoids, immunomodulatory drugs, BCL2 inhibitors, Bruton's tyrosine kinase inhibitors, spironolactone, PARP inhibitors, and proteasome inhibitors. Additional claims also cover routes of administration including intravenous and intraperitoneal delivery. A Notice of Allowance is issued after the USPTO determines that prosecution on the merits of a patent application has concluded, and the patent grants upon payment of the required issuance fee.